HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales von Thokala, Praveen, Carlson, Josh J., Drummond, Mike

Volltext

Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review von Chen, Yilin, Carlson, Josh J

Volltext

The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study von Adamson, Blythe, El-Sadr, Wafaa, Dimitrov, Dobromir, Gamble, Theresa, Beauchamp, Geetha, Carlson, Josh J., Garrison, Louis, Donnell, Deborah

Volltext

Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims... von Yang, Joseph, Boytsov, Natalie, Carlson, Josh J., Barthold, Douglas

Volltext

Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework von Jiao, Boshen, Carlson, Josh J., Garrison, Louis P., Basu, Anirban

Volltext

Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study von Regier, Dean A., Veenstra, David L., Basu, Anirban, Carlson, Josh J.

Volltext

Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer von Carlson, Josh J., Suh, Kangho, Orfanos, Panos, Wong, William

Volltext

How does cumulative evidence from older adult-specific trials influence clinical practice? A difference-in-differences analysis in early-stage breast cancer von Lee, Woojung, Basu, Anirban, Carlson, Josh J., Veenstra, David

Volltext

Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials von Bennette, Caroline S, Ramsey, Scott D, McDermott, Cara L, Carlson, Josh J, Basu, Anirban, Veenstra, David L

Volltext

Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study von Chen, Yilin, Martin, Peter, Inoue, Lurdes Y.T., Basu, Anirban, Carlson, Josh J.

Volltext

Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? von McQueen, R. Brett, Anderson, Kelly E., Levy, Joseph F., Carlson, Josh J.

Volltext

Cost Effectiveness of Pharmacogenomics: A Critical and Systematic Review von Wong, William B., Carlson, Josh J., Thariani, Rahber, Veenstra, David L.

Volltext

Use of real-world evidence in economic assessments of pharmaceuticals in the United States von Lee, Woojung, Dayer, Victoria, Jiao, Boshen, Carlson, Josh J., Devine, Beth, Veenstra, David L.

Volltext

Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome von Neuberger, Edward E., Carlson, Josh J., Veenstra, David L.

Volltext

Cost‐effectiveness analysis of low‐dose direct oral anticoagulant (DOAC) for the prevention of cancer‐associated thrombosis in the United States von Li, Ang, Carlson, Josh J., Kuderer, Nicole M., Schaefer, Jordan K., Li, Shan, Garcia, David A., Khorana, Alok A., Carrier, Marc, Lyman, Gary H.

Volltext

Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis von Chin, Lauren, Hansen, Ryan N., Carlson, Josh J.

Volltext

Assessing Payers’ Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment von Saldarriaga, Enrique M., Hauber, Brett, Carlson, Josh J., Barthold, Douglas, Veenstra, David L., Devine, Beth

Volltext

Authors’ Reply to Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome” von Neuberger, Edward E., Carlson, Josh J., Veenstra, David L.

Volltext

Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis von Zimmermann, Marita, Brouwer, Elizabeth, Tice, Jeffrey A., Seidner, Matt, Loos, Anne M., Liu, Shanshan, Chapman, Richard H., Kumar, Varun, Carlson, Josh J.

Volltext

Can we predict trial failure among older adult-specific clinical trials using trial-level factors? von Lee, Woojung, Basu, Anirban, Carlson, Josh J., Veenstra, David

Volltext